Upload File

fda initiative:

22
DRAFT-CONFIDENTIAL 1 FDA Initiative: Focus on Quality June 11, 2013 Francisco Vicenty 1

Upload: bly

Post on 23-Feb-2016

65 views

Category:

Documents


0 download

Report

Tags:

DESCRIPTION

FDA Initiative:. Focus on Quality June 11, 2013 Francisco Vicenty. 1. Agenda. What is the Focus on Quality project? 2012 Activities 2013 Plan. Focus on quality . Scope and Direction. Focus on Quality - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: FDA Initiative:

DRAFT-CONFIDENTIAL 1

FDA Initiative:

Focus on QualityJune 11, 2013

Francisco Vicenty

1

Page 2: FDA Initiative:

Agenda• What is the Focus on Quality project?• 2012 Activities• 2013 Plan

DRAFT-CONFIDENTIAL 2

Page 3: FDA Initiative:

3

Scope and Direction• Focus on Quality

• Encompasses FDA traditional approach to evaluating device quality: inspections, recalls, and postmarket issues.

• Our hypothesis:• When a firm has constant focus on assuring device

quality, why wouldn’t compliance be the outcome?

Focus on quality

Page 4: FDA Initiative:

• FoQ’s Methodology

DRAFT-CONFIDENTIAL 4

IndustryEngagement

Process

Interview/Assess

Evaluate/Modify

Pilot

Analyze

Scope and Direction

Page 5: FDA Initiative:

5

The FoQ Team• Kim Lewandowski-Walker

• ORA National Expert Investigator• Karen Masley-Joseph

• ORA Central Region, QS Manager• Keisha Thomas

• CDRH/OC, Division of Enforcement A• Cisco Vicenty

• CDRH/OC, Project Manager• Bill MacFarland

• CDRH/OC, Division of Enforcement B

Focus on quality

Page 6: FDA Initiative:

2012 Activities• Engage stakeholders to assess

quality/compliance perception gap– Manufacturers– CDRH Compliance Officers– ORA Investigators & Compliance Officers– International Regulatory Officials

DRAFT-CONFIDENTIAL 6

Page 7: FDA Initiative:

2012 Activities• Interview questions on FDA approach:

– On perceptions and definitions:• How do you define quality? Compliance? Overlap?

– On concepts:• Measures of quality• Tools and factors that impact on quality

– Recommendations:• King/queen for a day…

DRAFT-CONFIDENTIAL 7

Page 8: FDA Initiative:

2012 Activities• Manufacturer Feedback

– Maintaining compliance does not ensure good quality.

– FDA focuses purely on compliance and not on device quality.

– FDA’s indirect measure of a firm’s commitment to quality is the resources that the firm spends on quality.

DRAFT-CONFIDENTIAL 8

Page 9: FDA Initiative:

2012 Activities• CDRH Compliance Officer Feedback

– We do not focus on quality because that’s not what we’ve chosen to focus on.

– Significant interest in focusing on device quality, not just compliance.

– We need:• Work processes to focus on quality• More interaction with firms on quality• Resources

DRAFT-CONFIDENTIAL 9

Page 10: FDA Initiative:

2012 Activities• ORA Investigators & Compliance Officers

– Compliance programs are written to focus on compliance - quality outcomes are not captured.

– Seeking more collaborative interaction with firms during inspection, provide interpretation/advice on observations.

DRAFT-CONFIDENTIAL 10

Page 11: FDA Initiative:

2012 Activities• International Regulatory Official Interviews

(they promote a focus on quality through…)– Focusing on manufacturing processes that

directly relate to Critical to Quality.– Prioritizing audit findings based on criticality.– Focusing on how management ensures good

quality.– Interacting with firm to get them back to a

state of compliance.

DRAFT-CONFIDENTIAL 11

Page 12: FDA Initiative:

Onwards to 2013• What is this term, “Critical to Quality” we

heard about?

DRAFT-CONFIDENTIAL 12

“…the key output characteristic of a process. An example may be an element of a design or an attribute of a service that is critical in the eyes of the customer.”

- Implementing Quality: A Practical Guide to Tools and Techniques. By Ron Basu

“A CTQ is a product or service characteristic that must be met to satisfy a specification or requirement.”

- Six Sigma Best Practices. By Dhirendra Kumar

“Its purpose is to start with the high-level strategic goal of customer satisfaction and determine how this goal “flows down” into measureable goals.

- The Certified Six Sigma Handbook. By TM Kubiak and Donald W. Benbow

Page 13: FDA Initiative:

DRAFT-CONFIDENTIAL 13

What is this term, “Critical to Quality?”e.g., a “CtQ tree”

Page 14: FDA Initiative:

Onwards to 2013• Assessing the interview results

What can FDA do differently to drive more focus on what is “Critical to Quality”, not just compliance behaviors?

• Can we prepare investigators with CtQ information going into inspections?

• How can investigators triage their review of QMS subsystems based on CtQs?

• How can 483 observations be prioritized based on it’s correlation with a CtQ?

DRAFT-CONFIDENTIAL 14

Page 15: FDA Initiative:

Onwards to 2013• How do you define in your company what is

“Critical to Quality”, and why? • That which…

– Impacts the customer needs?• Limited to safety and effectiveness? Fitness for use?• Extends to customer satisfaction?• What about low risk dissatisfies?

– Only design features?– …or manufacturing process characteristics as well?– Are measureable?

DRAFT-CONFIDENTIAL 15

Page 16: FDA Initiative:

Beyond 2013• From the Case for Quality whitepaper1

– Compliance focused environment diverts resources away from quality investments

– There is little top management focus on quality performance

– Leadership “calibrates success” based on inspectional results

DRAFT-CONFIDENTIAL 16Note1 http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM277323.pdf

Page 17: FDA Initiative:

Beyond 2013• If the current inspectional outcomes are

focused on promoting “Compliance behaviors” i.e.– Inspectional Classifications:

• No Action Indicated• Voluntary Action Indicated• Official Action Indicated

DRAFT-CONFIDENTIAL 17

Page 18: FDA Initiative:

Beyond 2013• What kind of inspectional outcomes would

promote “Quality Behaviors” not just “Compliance Behaviors?”

• How can FDA’s approach to quality promote achievement of higher levels of execution?

DRAFT-CONFIDENTIAL 18

Page 19: FDA Initiative:

Beyond 2013• More specifically, aren’t there different

levels of quality system execution? e.g.– Deployment of proactive quality planning across

product lines– Proactive monitoring of quality characteristics that

prevent defects before they occur– Refining the approach to ensuring quality through

cycles of evaluation and improvement– Achieving breakthroughs in quality through

innovationDRAFT-CONFIDENTIAL 19

Page 20: FDA Initiative:

• So we are developing a hypothesis for the upcoming months/years:– If device firm leadership “calibrates success”

based on inspectional outcomes, do inspectional outcomes need to convey the levels of quality system execution?

DRAFT-CONFIDENTIAL 20

Beyond 2013

Page 21: FDA Initiative:

What you can expect• 2013

– FDA prototyping an inspectional approach that promotes more focus on Critical to Quality

• Beyond 2013– FDA engaging with stakeholders on additional

ways to update our approach with respect to device quality

DRAFT-CONFIDENTIAL 21

Page 22: FDA Initiative:

For the Breakout Session

• What can FDA do differently to drive more focus on what is “Critical to Quality”, not just compliance behaviors?

• How do you define in your company what is “Critical to Quality”, and why?

• What kind of inspectional outcomes would promote “Quality Behaviors” not just “Compliance Behaviors?”

DRAFT-CONFIDENTIAL 22

How can our approach be updated to focus more on device quality?


FDA - CAT002.E3 _ FDA 800_900

- ISA Tech Talk Agenda • History of FDA GMP initiative for the 21st Century. • Industry response to FDA initiative. • Harmonisation through ICH. • ASTM Standard on Risk Based

Report on the Pilot EMA-FDA GCP Initiative on the Pilot EMA-FDA GCP Initiative EXT/INS/GCP/56289/2011 Page 3/30 Report on the Pilot EMA-FDA GCP Initiative EXT/INS/GCP/56289/2011 Page

Food Labeling FDA Nutrition Facts FDA Nutrition Facts OriginalProposed

MCMi FDA launched its medical countermeasure initiative (MCMi) in response to a comprehensive, year‐long review conducted by the HHS assessing the nation’s

205750Orig1s000 - Food and Drug Administration...Feb 11, 2014  · Calbon . FDA . Drolban . FDA . Cholan-HBM . FDA . Cholesterol . External . Cholbam *** FDA . Clobazam . External,

IPEC Americas & IQ Consortium - FDA meeting to discuss ... Americas & IQ Consortium - FDA meeting to discuss Novel Excipients Initiative June 4, 2015 Attendees FDA STAFF ORGANIZATION:

FDA Overview of Molecular Diagnostics and the Critical Path … · FDA Overview of Molecular Diagnostics and the Critical Path Initiative Steven Gutman, MD, MBA Director, Office of

Value Initiative - Amazon S3 · 2019-11-25 · Procedures and Therapies” Summit • Providers, medical institutions, hospital administrators, FDA, CMS, Private payers, patient advocates,

FDA Alliance for a Stronger FDA

FDA Inspections ( How to Survive an FDA Inspection).ppt

Department of Biomedical Engineering, University of ......The Sentinel Initiative Unique Device Identification (UDI) System Johnson, J. A., FDA Regulation of Medical Devices, 2016

ICH Q9 ‘Quality Risk Management’ - National Institute of ... FDA Pharmaceutical GMP Initiative “seeks to integrate quality systems and risk management approaches into the existing

Global Medical Device Consulting - FDA Transparency Initiative: … · 2020-01-02 · Regulated industry provides the public with food, drugs, medical devices, cosmetics, and other

FDA “Critical Path” Initiative: Closing Productivity Gap ...schizophrenia, stroke, … Physicians – Need tools to better diagnose disease, Target therapies at the patients most

FDA guidance, FDA compliance, FDA consulting, FDA regulations, …compliancegurus.com/files/pharmamay09.pdf · 2018. 11. 12. · Data integrity was seen in the Warning Letter sent

FDA/Industry Workshop September 14-16, 2005 Critical Path Initiative: What it means for pharmaceutical industry statisticians Walter Offen, Lilly Brenda

DHHS / FDA / CDRH 1 FDA Summary CryoLife BioGlue P010003 Lead FDA Reviewer Lisa Kennell

Introduction to OARSI FDA initiative OAC special editionIntroduction to OARSI FDA initiative OAC special edition Since July 1999, the Food and Drug Administration (FDA) has provided

THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 · 2018-12-13 · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDAGrop.com 4 FDA 483 RESOLVING FDA 483 OBSERVATIONS

Liberia Extractive Industries Transparency Initiative · Dev. Development EITI Extractive Industries Transparency Initiative ELWA Eternal Love Wining Africa FDA Forestry Development

FDA Method Development and Regulatory Application in ... · FSMA Rules & Requirements FDA Regulatory Compliance FDA Lab Requirements & ISO Standards FDA Science Research State, Federal,

FDA Critical Path Initiative: A Generic Industry Perspective

FDA Oral History Interviews, FDA retired scientists

FDA Medical Countermeasures Initiative (MCMi)

FDA TA Initiative Project Plan

The FDA Critical Path Initiative In Vitro Techniques and ... · Deposition of Particles in the Lung Mechanisms of deposition: –Inertial impaction (d a > 1μm) –Sedimentation

FDA PACIFIC REGION RETAIL FOOD SEMINAR - … · Web viewUS FDA Other titles FDA PACIFIC REGION RETAIL FOOD SEMINAR

NICHD/FDA Newborn Drug Development Initiative Workshop I

Excipients data sharing initiative: a step towards 3-R ... data... · Excipients are crucial assets in pharmaceutical formulations. ... FDA Guidance for Industry Nonclinical Studies

FDA: Feature Disruptive Attack - openaccess.thecvf.comopenaccess.thecvf.com/content_ICCV_2019/papers/... · motivation, we introduce FDA: Feature Disruptive attack. FDA generates

FDA Perspective: FDA Evaluation of Point of Care … How FDA reviews...1 FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters Patricia Bernhardt, M.T.(ASCP), Scientific

SPOT/Dx Diagnostic Quality Assurance Pilot · – Advent of NIH Precision Medicine Initiative (PMI) – FDA January 2017 LDT oversight discussion paper – Existing standardization

FDA Presentation FDA Presentation

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez)